Logo 1.png
Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates
August 04, 2021 16:05 ET | Aeterna Zentaris Inc
– Company continues to advance clinical and preclinical programs with its diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need – Strong...
Logo 1.png
Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs
June 07, 2021 08:05 ET | Aeterna Zentaris Inc
– Dr. Levy is a well-established neuroimmunologist with extensive experience and expertise in the area of neuroimmunology, autoimmune and CNS disorders – Company continues to advance development of...
Logo 1.png
Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit
June 03, 2021 08:05 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., June 03, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Logo 1.png
Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders
May 05, 2021 16:35 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
Logo 1.png
Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares
February 19, 2021 13:25 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Logo 1.png
Aeterna Zentaris to Present at NobleCon17
January 15, 2021 08:05 ET | Aeterna Zentaris Inc
– Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, January 20th at 12:00 PM ET – CHARLESTON, S.C., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)...